We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DNA Analysis Systems Reduce DNA Input and Increase Sample Throughput

By Labmedica staff writers
Posted on 16 Jan 2008
Two new products for DNA analysis double sample throughput and reduce DNA input requirements by as much as 70%. More...
They offer enhanced signal discrimination and a new single nucleotide polymorphism (SNP) algorithm.

Launched by Illumina's (San Diego, CA, USA) microarray business, the two new products are on the Human1M-Duo beadchip and contain markers for more than one million diverse genetic variants, all of which can be used for both whole-genome genotyping and copy number variation (CNV) analysis.

In addition to Human1M single-sample BeadChip, Illumina's new Human1M-Duo features can identify disease-associated SNPs and intelligently select high-density SNPs in coding regions of the genome. The Human1M-Duo also provides the highest available power to detect SNPs associated with diseases and the least number of large gaps for the identification of CNVs.
The Infinium HD Human1M-Duo (two samples/chip) and the Human610-Quad (four samples/chip), feature up to 2.3 million single nucleotide polymorphisms (SNPs) per beadchip. First customer shipments of the Human610-Quad and Human1M-Duo beadchips are expected in the first and second quarters of 2008, respectively.

The four-sample format of the Human610-Quad beadchip provides customers with a significant increase in sample throughput and reduced handling in the lab. Built upon the content of Illumina's broadly adopted HumanHap550 beadchip, the Human610-Quad beadchip has 550,000 SNPs plus an additional 60,000 genetic markers per sample. Both the Infinium HD Human1M-Duo and Human610-Quad beadchips include high-value, CNV content developed in conjunction with deCODE genetics, only found on Illumina arrays.

"The Human1M-Duo and Human610-Quad beadchips provide our customers with significant advances, including increased sample throughput, lower input sample volume, and improvements to the Infinium assay that enhance overall system performance. Concurrent with the development of these new array products, Illumina has implemented new decoding instruments into its operations that will effectively double Illumina's array manufacturing capacity over the next several quarters,” said John Stuelpnagel, senior vice president, COO, and general manager of Illumina's Microarray Business.

Illumina's genotyping solutions offer a flexible beadchip design and high-density architecture. Infinium HD products provide a powerful complement to Illumina's genotyping offering, which includes Infinium II, iSelect Infinium, GoldenGate, and VeraCode genotyping products.


Related Links:
Illumina

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
POC Immunoassay Analyzer
Procise DX
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.